As a comprehensive study of pre-manifest and early HD, TRACK-HD aims to measure the sensitivity of individual and combined assessment tools to detect subtle changes in disease progression. The ultimate goal is to establish what combination of measures is the most sensitive for detecting change over the natural course of HD. This would lay the foundations to develop the much-needed methodology to undertake future clinical trials of disease-modifying agents in HD.